Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $49.7 million.

  • Oncology Institute's Cash & Equivalents fell 4165.23% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year decrease of 4165.23%. This contributed to the annual value of $49.7 million for FY2024, which is 4831.88% up from last year.
  • Latest data reveals that Oncology Institute reported Cash & Equivalents of $49.7 million as of FY2024, which was up 4831.88% from $33.5 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Cash & Equivalents registered a high of $115.2 million during FY2021, and its lowest value of $6.0 million during FY2020.
  • Its 5-year average for Cash & Equivalents is $43.7 million, with a median of $33.5 million in 2023.
  • In the last 5 years, Oncology Institute's Cash & Equivalents surged by 182020.67% in 2021 and then plummeted by 8783.58% in 2022.
  • Over the past 5 years, Oncology Institute's Cash & Equivalents (Annual) stood at $6.0 million in 2020, then skyrocketed by 1820.21% to $115.2 million in 2021, then tumbled by 87.84% to $14.0 million in 2022, then soared by 139.03% to $33.5 million in 2023, then soared by 48.32% to $49.7 million in 2024.
  • Its Cash & Equivalents stands at $49.7 million for FY2024, versus $33.5 million for FY2023 and $14.0 million for FY2022.